A case report of retroperitoneal dedifferentiated chondrosarcoma with femoral nerve involvement
DOI:
https://doi.org/10.18203/2320-6012.ijrms20250274Keywords:
Dedifferentiated chondrosarcoma, Femoral nerve, Wide local excision, Knee gaiter, Sural nerve graftAbstract
Chondrosarcomas, a type of malignant bone tumour, are relatively rare and originate from cartilage producing cells. Dedifferentiated chondrosarcoma (DDCS), which makes up about 10% of all chondrosarcomas, is a rare and extremely aggressive subtype with high risk of metastasis. Here we report a case of 60-year-old lady with left lower abdomen lump of 10x10cm since 5months with normal gait, normal sensory, motor, spine and hip examination which shows no bony involvement in X-rays. On CECT and MRI there was large heterogenous enhancing soft tissue density mass lesion of size 11.7×10.9 cm with multiple coarse calcifications, without bone involvement. On Ultrasound guided core needle biopsy, it was found to be low grade chondrosarcoma. Patient was planned for wide local excision of tumor with adequate margins. Intraoperatively femoral nerve was seen passing inside the tumor which was resected and nerve repair done with sural nerve graft. In Post operative period patient had difficulty in extending left leg so knee gaiter was advised for support. After 6months follow up patient was seen healthy and walking without knee gaiter. Dedifferentiated chondrosarcoma (DDCS), which makes up about 10% of all chondrosarcomas, is a rare and extremely aggressive subtype. It is associated with high rates of metastasis and poor survival. Surgery is generally the standard of care for patients and adequate margins are recommended. Role of chemoradiotherapy is controversial. Surgery is the treatment of choice in dedifferentiated chondrosarcoma in patients with local disease with no metastasis.
Metrics
References
Anfinsen KP, Devesa SS, Bray F, Troisi R, Jonasdottir TJ, Bruland OS, et al. Age-period-cohort analysis of primary bone cancer incidence rates in the United States (1976–2005). Cancer Epidemiol Prev Biomark. 2011;20:1770-7. DOI: https://doi.org/10.1158/1055-9965.EPI-11-0136
Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and ewing’s sarcoma: national cancer data base report. Clin Orthop Relat Res. 2007;459:40–7. DOI: https://doi.org/10.1097/BLO.0b013e318059b8c9
Giuffrida AY, Burgueno JE, Koniaris LG, Gutierrez JC, Duncan R, Scully SP. Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. JBJS. 2009;91(5):1063-72. DOI: https://doi.org/10.2106/JBJS.H.00416
Gusho CA, Lee L, Zavras A. Dedifferentiated Chondrosarcoma: A Case Series and Review of the Literature. Orthopedic Reviews. 2022;14(3):448. DOI: https://doi.org/10.52965/001c.35448
Estrada EG, Ayala AG, Valerie L, Czerniak B. Dedifferentiated chondrosarcoma with a noncartilaginous component mimicking a conventional giant cell tumor of bone. Annals of Diagnostic Pathology. 2002;6(3):159-63. DOI: https://doi.org/10.1053/adpa.2002.33905
Bharath G, Burrah R, Shivakumar K, Manjunath S, Bhanumathi R. Dedifferentiated chondrosarcoma: an aggressive variant of chondrosarcoma. Asian Cardiovas Thor Ann. 2015;23(2):221-3. DOI: https://doi.org/10.1177/0218492314522253
Deloin X, Dumaine V, Biau D, Karoubi M, Babinet A, Tomeno B, et al. Pelvic chondrosarcomas: surgical treatment options. Orthopaed Traumatol Surg Res. 2009;95(6):393-401. DOI: https://doi.org/10.1016/j.otsr.2009.05.004
Coşkun HS, Erdoğan F, Büyükceran İ, Dabak N. Evaluation of prognostic factors affecting survival in chondrosarcoma treatment and comparison with literature. Joint Diseases and Related Surg. 2022;33(2):440. DOI: https://doi.org/10.52312/jdrs.2022.526
Grimer RJ, Gosheger G, Taminiau A, Biau D, Matejovsky Z, Kollender Y, et al. Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group. European J Can. 2007;43(14):2060-5. DOI: https://doi.org/10.1016/j.ejca.2007.06.016